Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration

Ophthalmology

Volumn 121, Issue 4, 2014, Pages 936-945

  Stein, Joshua D ^a   Newman Casey, Paula Anne ^a   Mrinalini, Tavag ^b   Lee, Paul P ^a   Hutton, David W ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BLINDNESS; BUDGET; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; HEART INFARCTION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDICARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SYSTEMIC DISEASE; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84897954586     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.10.037     Document Type: Article

References (54)

1. National Advisory Eye Council. Vision Research, a National Plan, 1994-1998. Washington, DC: US Department of Health and Human Services; 1993. NIH publication 93-3186.
2. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
3. R. Klein, B.E. Klein, and K.L. Linton Prevalence of age-related maculopathy: the Beaver Dam Eye Study Ophthalmology 99 1992 933 943
4. J.B. Hassell, E.L. Lamoureux, and J.E. Keeffe Impact of age related macular degeneration on quality of life Br J Ophthalmol 90 2006 593 596
5. K. Scilley, G.R. Jackson, and A.V. Cideciyan et al. Early age-related maculopathy and self-reported visual difficulty in daily life Ophthalmology 109 2002 1235 1242
6. Macular Photocoagulation Study Group Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial Arch Ophthalmol 100 1982 912 918
7. Macular Photocoagulation Study Group Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials Arch Ophthalmol 109 1991 1109 1114
8. R. Wormald, J. Evans, L. Smeeth, and K. Henshaw Photodynamic therapy for neovascular age-related macular degeneration Cochrane Database Syst Rev 3 2005 CD002030
9. P.J. Rosenfeld, D.M. Brown, and J.S. Heier et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
10. D.M. Brown, P.K. Kaiser, and M. Michels et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
11. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
12. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, M.G. Maguire, and S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
13. G.C. Brown, M.M. Brown, and H.C. Brown et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration Ophthalmology 114 2007 1170 1178
14. D.H. Smith, P. Fenn, and M. Drummond Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case Br J Ophthalmol 88 2004 1107 1112
15. J.L. Colquitt, J. Jones, and S.C. Tan et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation Health Technol Assess 12 2008 iii-iv, ix-201
16. J.C. Javitt, G.P. Zlateva, and S.R. Earnshaw et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity Value Health 11 2008 563 574
17. S.E. Wolowacz, N. Roskell, and S. Kelly et al. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK Pharmacoeconomics 25 2007 863 879
18. M.M. Brown, G.C. Brown, H.C. Brown, and J. Peet A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration Ophthalmology 115 2008 1039 1045
19. Common Drug Review Overview of CDR clinical and pharmacoeconomic reports. Ranibizumab (Lucentis-Novartis Pharmaceuticals Canada Inc), Indication-age-related macular degeneration (AMD) 2008 Canadian Agency for Drugs and Technologies in Health Ottawa, ON Available at: http://www.cadth.ca/media/ cdr/relatedinfo/cdr-trans-Lucentis-overview-Jul-30-08-e.pdf Accessed October 20, 2013
20. S.F. Hurley, J.P. Matthews, and R.H. Guymer Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration Cost Eff Resour Alloc [serial online] 6 2008 12 Available at: http://www.resource-allocation. com/content/6/1/12 Accessed October 20, 2013
21. A. Brown, W. Hodge, and S. Kymes et al. Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation [technology report number 110] 2008 Canadian Agency for Drugs and Technologies in Health Ottawa, ON 30-4. Available at: http://www.cadth.ca/en/ products/health-technology-assessment/publication/813 Accessed May 31, 2013
22. E.C. Fletcher, R.J. Lade, T. Adewoyin, and N.V. Chong Computerized model of cost-utility analysis for treatment of age-related macular degeneration Ophthalmology 115 2008 2192 2198
23. L.J. Hernandez-Pastor, A. Ortega, A. Garcia-Layana, and J. Giraldez Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 248 2010 467 476
24. P. Mitchell, L. Annemans, and R. White et al. Cost effectiveness of treatments for wet age-related macular degeneration Pharmacoeconomics 29 2011 107 131
25. J. Raftery, A. Clegg, and J. Jones et al. Ranibizumab (Lucentis) versus Bevacizumab (Avastin): modelling cost effectiveness Br J Ophthalmol 91 2007 1244 1246
26. J.J. Patel, M.A. Mendes, and M. Bounthavong et al. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model J Eval Clin Pract 18 2012 247 255
27. Dooren JC, Whalen J. Study compares Lucentis, Avastin. The Wall Street Journal. April 28, 2011.
28. Medicare payments for drugs used to treat wet age-related macular degeneration (OEI-03-10-00360). Department of Health and Human Services, Office of Inspector General; 2012. Available at: https://oig.hhs.gov/oei/reports/oei- 03-10-00360.pdf. Accessed October 20, 2013.
29. M.F. Drummond, M.J. Sculpher, and G.W. Torrance et al. Methods for the Economic Evaluation of Health Care Programmes 3rd ed. 2005 Oxford University Press Oxford 277-322
30. G.A. Lalwani, H.W. Flynn Jr., and I.U. Scott et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005): clinical features, causative organisms, and visual acuity outcomes Ophthalmology 115 2008 473 476
31. Endophthalmitis Vitrectomy Study Group Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis Arch Ophthalmol 113 1995 1479 1496
32. Centers for Disease Control and Prevention CDC WONDER. Underlying Cause of Death, 1999-2010 [database online] Revised 2012 Available at: http://wonder.cdc.gov/ucd-icd10.html Accessed May 31, 2013
33. K.D. Frick, E.W. Gower, J.H. Kempen, and J.L. Wolff Economic impact of visual impairment and blindness in the United States Arch Ophthalmol 125 2007 544 550
34. C.E. Mahan, M.E. Borrego, and A.L. Woersching et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates Thromb Haemost 108 2012 291 302
35. D.A. MacDougall, A.L. Feliu, S.J. Boccuzzi, and J. Lin Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome Am J Health Syst Pharm 63 suppl 2006 S5 15
36. J.V. Freeman, R.P. Zhu, and D.K. Owens et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
37. M.M. Brown, G.C. Brown, S. Sharma, and J. Landy Health care economic analyses and value-based medicine Surv Ophthalmol 48 2003 204 223
38. T.M. Aaberg Jr., H.W. Flynn Jr., J. Schiffman, and J. Newton Nosocomial acute-onset postoperative endophthalmitis surgery. A 10-year review of incidence and outcomes Ophthalmology 105 1998 1004 1010
39. P.S. Bajaj, and D.L. Veenstra A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics Genet Med 15 2013 374 381
40. Red Book Drug References [database]. Truven Health Analytics Inc.
41. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York 276-303
42. P.A. Ubel, R.A. Hirth, M.E. Chernew, and A.M. Fendrick What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 2003 1637 1641
43. G.C. Brown, M.M. Brown, and S. Sharma et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization Ophthalmology 107 2000 1374 1380
44. B.G. Busbee, M.M. Brown, G.C. Brown, and S. Sharma CME review: a cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization Retina 23 2003 279 287
45. K. Larouche, S. Rochon, and M. Wickens translator. Evaluation of photodynamic therapy for the treatment of exudative age-related macular degeneration (ARMD) with subfoveal neovascularization 2005 Agence d' évaluation des technologies et des modes d' intervention en santé Montreal 32-42. Available from: http://collections.banq.qc.ca/ark:/52327/bs52604 Accessed October 20, 2013
46. G.C. Brown, M.M. Brown, J. Campanella, and G.R. Beauchamp The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-A value-based reappraisal with 5-year data Am J Ophthalmol 140 2005 679 687
47. C. Hopley, G. Salkeld, and P. Mitchell Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration Br J Ophthalmol 88 2004 982 987
48. C. Meads, C. Salas, and T. Roberts et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation Health Technol Assess 7 2003 v-vi,1-98
49. S. Sharma, G.C. Brown, and M.M. Brown et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 108 2001 2051 2059
50. IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
51. Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis [press release]. Basel, Switzerland: Novartis; May 1, 2012. Available from: http://www.novartis.com/ newsroom/media-releases/en/2012/1607728.shtml. Accessed August 22, 2013.
52. F. Kabbinavar, H.I. Hurwitz, and L. Fehrenbacher et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
53. M.A. Shah, D. Ilson, and D.P. Kelsen Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy [letter] J Clin Oncol 23 2005 2574 2576
54. Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab [report online]. Acta Ophthalmol 2012;90:e25-30. Available at: http://onlinelibrary.wiley.com/doi/10. 1111/j.1755-3768.2011.02240.x/pdf. Accessed October 20, 2013.